Does the media favor ORIC or ACAD?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.90 beat Oric Pharmaceuticals' score of 0.49 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORIC or NAMS?

In the previous week, Oric Pharmaceuticals had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 2 mentions for NewAmsterdam Pharma. Oric Pharmaceuticals' average media sentiment score of 0.49 beat NewAmsterdam Pharma's score of 0.39 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ORIC or DNLI more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Denali Therapeutics N/A -52.20% -43.86%

Does the media favor ORIC or DNLI?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 4 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.80 beat Oric Pharmaceuticals' score of 0.49 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ORIC or DYN?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is ORIC or DYN more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Dyne Therapeutics N/A -58.28% -46.77%

Does the media prefer ORIC or DYN?

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Dyne Therapeutics. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.26 beat Oric Pharmaceuticals' score of 0.49 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORIC or CPRX?

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 5 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.87 beat Oric Pharmaceuticals' score of 0.49 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Catalyst Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oric Pharmaceuticals (ORIC) Competitors

$10.73 0.00 (0.00%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$10.74 +0.01 (+0.07%)

As of 04:12 AM Eastern

Compare

ORIC vs. ACAD, NAMS, DNLI, DYN, and CPRX

Should you buy Oric Pharmaceuticals stock or one of its competitors? MarketBeat compares Oric Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oric Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Dyne Therapeutics (DYN), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Oric Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
ACADIA Pharmaceuticals	$1.07B	4.09	$391M	$2.20	11.64

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Oric Pharmaceuticals' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Oric Pharmaceuticals currently has a consensus price target of $19.27, suggesting a potential upside of 79.62%. ACADIA Pharmaceuticals has a consensus price target of $32.94, suggesting a potential upside of 28.68%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 4 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.90 beat Oric Pharmaceuticals' score of 0.49 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Oric Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to NewAmsterdam Pharma?

Oric Pharmaceuticals (NASDAQ:ORIC) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Oric Pharmaceuticals has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
NewAmsterdam Pharma	$22.50M	164.60	-$203.82M	-$1.79	N/A

Oric Pharmaceuticals has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Oric Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

In the previous week, Oric Pharmaceuticals had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 2 mentions for NewAmsterdam Pharma. Oric Pharmaceuticals' average media sentiment score of 0.49 beat NewAmsterdam Pharma's score of 0.39 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Oric Pharmaceuticals currently has a consensus target price of $19.27, suggesting a potential upside of 79.62%. NewAmsterdam Pharma has a consensus target price of $49.00, suggesting a potential upside of 54.67%. Given Oric Pharmaceuticals' higher possible upside, equities research analysts clearly believe Oric Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Oric Pharmaceuticals beats NewAmsterdam Pharma on 10 of the 16 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Denali Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Oric Pharmaceuticals currently has a consensus price target of $19.27, suggesting a potential upside of 79.62%. Denali Therapeutics has a consensus price target of $35.08, suggesting a potential upside of 50.64%. Given Oric Pharmaceuticals' higher probable upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oric Pharmaceuticals' return on equity of -35.33% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Denali Therapeutics	N/A	-52.20%	-43.86%

Oric Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 4 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.80 beat Oric Pharmaceuticals' score of 0.49 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Denali Therapeutics	$330.53M	11.18	-$512.54M	-$2.88	N/A

Summary

Oric Pharmaceuticals beats Denali Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Oric Pharmaceuticals' return on equity of -35.33% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Dyne Therapeutics	N/A	-58.28%	-46.77%

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Dyne Therapeutics. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.26 beat Oric Pharmaceuticals' score of 0.49 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals currently has a consensus price target of $19.27, indicating a potential upside of 79.62%. Dyne Therapeutics has a consensus price target of $34.17, indicating a potential upside of 43.92%. Given Oric Pharmaceuticals' higher probable upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Oric Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

Oric Pharmaceuticals and Dyne Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Catalyst Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Catalyst Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Oric Pharmaceuticals has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Oric Pharmaceuticals presently has a consensus target price of $19.27, indicating a potential upside of 79.62%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 1.62%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Oric Pharmaceuticals' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 6 mentions for Oric Pharmaceuticals and 5 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.87 beat Oric Pharmaceuticals' score of 0.49 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats Oric Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Oric Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORIC vs. The Competition

Export

Metric	Oric Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.11B	$3.69B	$6.86B	$12.27B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-7.45	21.21	27.26	23.92
Price / Sales	N/A	304.52	581.28	113.62
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	2.75	8.28	10.61	6.18
Net Income	-$129.47M	$23.81M	$3.59B	$331.89M
7 Day Performance	2.58%	-1.34%	-1.01%	-1.22%
1 Month Performance	26.38%	2.68%	1.65%	-1.30%
1 Year Performance	-2.54%	45.93%	25.62%	17.74%

Oric Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORIC Oric Pharmaceuticals	2.0519 of 5 stars	$10.73 flat	$19.27 +79.6%	-2.5%	$1.11B	N/A	N/A	80	Positive News
ACAD ACADIA Pharmaceuticals	4.8101 of 5 stars	$25.50 -2.7%	$32.94 +29.2%	+13.5%	$4.49B	$1.07B	11.59	510
NAMS NewAmsterdam Pharma	2.8447 of 5 stars	$33.28 -5.6%	$49.00 +47.2%	+42.7%	$4.12B	$22.50M	N/A	4	Positive News
DNLI Denali Therapeutics	3.1212 of 5 stars	$26.48 +3.1%	$34.75 +31.2%	+66.4%	$4.08B	$330.53M	N/A	430	Gap Down
DYN Dyne Therapeutics	3.3766 of 5 stars	$23.64 +0.9%	$34.17 +44.5%	+163.2%	$3.87B	N/A	N/A	100	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORIC) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. ACAD, NAMS, DNLI, DYN, and CPRX

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does Oric Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

How does Oric Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. ACAD, NAMS, DNLI, DYN, and CPRX

How does Oric Pharmaceuticals compare to ACADIA Pharmaceuticals?

Which has more risk and volatility, ORIC or ACAD?

Which has higher earnings and valuation, ORIC or ACAD?

Is ORIC or ACAD more profitable?

Do analysts rate ORIC or ACAD?

Does the media favor ORIC or ACAD?

Do institutionals and insiders hold more shares of ORIC or ACAD?

Summary

How does Oric Pharmaceuticals compare to NewAmsterdam Pharma?

Which has higher valuation & earnings, ORIC or NAMS?

Is ORIC or NAMS more profitable?

Which has more volatility & risk, ORIC or NAMS?

Does the media favor ORIC or NAMS?

Do institutionals & insiders hold more shares of ORIC or NAMS?

Do analysts prefer ORIC or NAMS?

Summary

How does Oric Pharmaceuticals compare to Denali Therapeutics?

Do analysts rate ORIC or DNLI?

Do institutionals and insiders hold more shares of ORIC or DNLI?

Is ORIC or DNLI more profitable?

Which has more risk & volatility, ORIC or DNLI?

Does the media favor ORIC or DNLI?

Which has stronger valuation & earnings, ORIC or DNLI?

Summary

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Is ORIC or DYN more profitable?

Do institutionals & insiders believe in ORIC or DYN?

Does the media prefer ORIC or DYN?

Do analysts recommend ORIC or DYN?

Which has stronger earnings & valuation, ORIC or DYN?

Which has more volatility and risk, ORIC or DYN?

Summary

How does Oric Pharmaceuticals compare to Catalyst Pharmaceuticals?

Which has better valuation & earnings, ORIC or CPRX?

Which has more risk & volatility, ORIC or CPRX?

Do analysts recommend ORIC or CPRX?

Is ORIC or CPRX more profitable?

Does the media favor ORIC or CPRX?

Do institutionals and insiders believe in ORIC or CPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools